AD_____

Award Number: W81XWH-05-1-0562

TITLE: Molecular and Clinical Predictors of Aggressive Prostate Cancer

PRINCIPAL INVESTIGATOR: Lorelei A. Mucci

CONTRACTING ORGANIZATION: Brigham and Women's Hospital Boston MA 02115

REPORT DATE: September 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Including States three states of the state is approximately approximate in the states of the stat	R	FPORT DO		N PAGE		Form Approved		
ada usek alid outpeng of menerging of medical of interact. Seriosmethy against an use of the start of the calculation of the mener of the calculation of the calculation of the mener of the calculation of the calculation of the mener of the calculation of	Public reporting burden for this	collection of information is es	timated to average 1 hour per res	ponse, including the time for revi	iewing instructions, searc	ching existing data sources, gathering and maintaining the		
Bigs Description Description <thdescription< th=""> <thdescription< th=""> <thdes< td=""><td>data needed, and completing an this burden to Department of De</td><td>nd reviewing this collection of efense. Washington Headqua</td><td>information. Send comments reg</td><td>arding this burden estimate or a prmation Operations and Reports</td><td>ny other aspect of this co (0704-0188) 1215 Jeffe</td><td>ollection of information, including suggestions for reducing erson Davis Highway, Suite 1204, Arlington, VA, 22202-</td></thdes<></thdescription<></thdescription<>	data needed, and completing an this burden to Department of De	nd reviewing this collection of efense. Washington Headqua	information. Send comments reg	arding this burden estimate or a prmation Operations and Reports	ny other aspect of this co (0704-0188) 1215 Jeffe	ollection of information, including suggestions for reducing erson Davis Highway, Suite 1204, Arlington, VA, 22202-		
AREPORT DATE (OLMARYNY) IN APPORT TYPE 3. DATES COVERED (From - Try) 0/09/06 Annual 1. Sep 2005 - 31 Aug 2006 4. TITLE AND SUBTITLE So. CONTRACT NUMBER Molecular and Clinical Predictors of Aggressive Prostate Cancer 5. CRANT NUMBER Structure 5. CRANT NUMBER Molecular and Clinical Predictors of Aggressive Prostate Cancer 5. CRANT NUMBER Structure 5. CRANT NUMBER Correlation 5. CRANT NUMBER Structure 5. CRANT NUMBER Structure 5. CRANT NUMBER Structure 5. CRANT NUMBER Correlation 5. CRANT NUMBER Structure 5. CRANT NUMBER Structure 5. CRANT NUMBER Structure 5. CRANT NUMBER Structure 5. SUBJECT NUMBER Structure 5. SPONSORING ORGANIZATION NAME(S) AND ADDRESS(ES) Brigham and Women's Hospital 5. PERFORMING ORGANIZATION REPORT Structure 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABULITY STATEMENT Approved for Public Releases to M	4302. Respondents should be	aware that notwithstanding a	ny other provision of law, no perso	on shall be subject to any penalty	y for failing to comply with	a collection of information if it does not display a currently		
01/09/06 1 Sep 2005 - 31 Åug 2006 4. TITLE AND SUBTITLE 56. CONTRACT NUMBER Molecular and Clinical Predictors of Aggressive Prostate Cancer 56. GRANT NUMBER 0.102/07/08 56. FROMT NUMBER	1. REPORT DATE (DD	-MM-YYYY)	2. REPORT TYPE	KE33.	3. 0	DATES COVERED (From - To)		
4. TITLE AND SUBTITLE Ss. CONTRACT NUMBER Molecular and Clinical Predictors of Aggressive Prostate Cancer Ss. CONTRACT NUMBER So. AUTHOR(5) Sc. GARNI NUMBER Lorelei A. Mucci Sc. FROGRAM ELEMENT NUMBER Se. AUTHOR(5) Sc. FASK NUMBER Lorelei A. Mucci Sc. TASK NUMBER E-Mail: lorelsi.mucci@hsph.harvard.edu Sc. TASK NUMBER 7. PERFORMING ORGANIZATION NAME(5) AND ADDRESS(ES) S. PERFORMING ORGANIZATION REPORT Brigham and Women'S Hospital Sc. PROSOR/MONITOR'S ACRONYM(S) 10. SPONSOR/ING / MONITORING AGENCY NAME(5) AND ADDRESS(ES) In SPONSOR/ING/ING'S REPORT U.S. Army Medical Research and Material Command For Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) In SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release, Distribution Unlimited 13. SUPPLEMENTARY NOTES St. ABSTRACT: The current project seeles to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer access in the cohort, to battract clinical data, and are assembling a clinical data[id.atmos operation to files press optical for the press on a studial ecoder access on the physical molecular equilation of the press on studial ecoder access on the cohort, to battract clinical data, and are assembling a clinical data[id.atmos optical for presses on for the press on studial ecoder acces on t	01/09/06		Annual		1 5	Sep 2005 – 31 Aug 2006		
Molecular and Clinical Predictors of Aggressive Prostate Cancer 56. GRANT NUMBER W11XWH-0.51.0662 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(§) Lorelei A. Mucci 54. PROJECT NUMBER 7. PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$) 56. TASK NUMBER 8. PROPORTING ORGANIZATION NAME(\$) AND ADDRESS(E\$) 8. PERFORMING ORGANIZATION REPORT Brigham and Women'S Hospital Boston MA 02115 9. PERFORMING ORGANIZATION REPORT 9. SPONSOR/MONITOR'NG AGENCY NAME(\$) AND ADDRESS(E\$) 8. PERFORMING ORGANIZATION REPORT 9. SPONSOR/MONITOR'NG AGENCY NAME(\$) AND ADDRESS(E\$) 10. SPONSOR/MONITOR'S ACRONYM(\$) 11. SPONSOR/MONITOR'S ACRONYM(\$) 11. SPONSOR/MONITOR'S ACRONYM(\$) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(\$) 13. SUPPLEMENTARY NOTES 14. SUPPLEMENTARY NOTES 14. SUPPLEMENTARY NOTES 14. SUPPLEMENTARY NOTES 15. SUBJECT TERMS No subject terms provided 17. LINITATION Net statistical leases and model building strategies for both sets of markets. 16. SUBJECT TERMS No subject TERMS No subject TERMS No subject TERMS No subject TERMS 18. NUMBER 19a. NAME OF RESPONSIBLE FERSON USAMR/NCC	4. TITLE AND SUE	BTITLE			5a.	CONTRACT NUMBER		
Molecular and Clinical Predictors of Aggressive Prostate Cancer Bb. GRATT WUMBER W11 WH-05-1-0562 Sc. PROGRAM ELEMENT NUMBER G. AUTHOR(S) Lorelei A. Mucci Se. TASK NUMBER Se. TASK								
W1 1XWHOG-1-0562 6. AUTHOR(5) Lorelei A. Mucci E-Mail: Iorelei mucci@hsph.harvard.edu 7. PERFORMING ORGANIZATION NAME(5) AND ADDRESS(E5) Brigham and Women's Hospital Boston MA 02115 9. SPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS(E5) U.S. Army Medical Research and Materiel Command Fort J. Suppresent of the second material command For Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(5) 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prestate cancer in two large US cohorts of prestate cancer in two large US cohorts of medical records from the Physicians' Health Study (PHS) and the Health Professional Follow-up. Study (PHS). We have admast completed review of medical records from the Physicians' Health Study (PHS) and the Health Professional Follow-up. Study (PHS). We have admast completed review of medical records from the Physicians' Health Study (PHS) and the Health Professional Follow-up. Study (PHS). We have admast completed review of medical records from the Physicians' Health Study (PHS) and the Health Professional Follow-up. Study (PHS). We have admast completed review of medical records from the Physicians' Health Study (PHS) and the Health Professional Follow-up. Study (PHS). We have admast completed review of medical records from the Physicians' Health Study (PHS). 13. SUPPLEMENTARY NOTES 14. ASSTRACT: The current project seeks to study molecu	Molecular and Clin	ical Predictors of	Aggressive Prostate	Cancer	5b.	GRANT NUMBER		
6. AUTHOR(\$) 5c. PROGRAM ELEMENT NUMBER Lorelei A, Mucci 5d. PROJECT NUMBER E-Mail: lorelei.mucci@hsph.harvard.edu 5r. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$) 8. PERFORMING ORGANIZATION REPORT Brigham and Women's Hospital 9. SPONSORIMO / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$) 8. PERFORMING ORGANIZATION REPORT U.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(\$) 11. SPONSOR/MONITOR'S ACRONYM(\$) V.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT V.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT V.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT V.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release, Distribution Unlimited 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The ourrent project seeks to study molecular and clinical predictors of aggressive presiste cancer in two large US cohorts of presiste cancer assess into don't to abstract cancer 14. SUBJECT TERMS No subject terms provided 16. SUBJECT TERMS			00		W	/81XWH-05-1-0562		
6. AUTHOR(5) Lorelei A. Mucci 5d. PROJECT NUMBER E-Mail: lorelei mucci@hsph.harvard.edu 5e. TASK NUMBER 7. PERFORMING ORGANIZATION NAME(5) AND ADDRESS(ES) 5. PERFORMING ORGANIZATION RAME(5) AND ADDRESS(ES) 5. PERFORMING ORGANIZATION RAME(5) AND ADDRESS(ES) Brigham and Women's Hospital Boston MA 02115 5. PERFORMING ORGANIZATION RAME(5) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(5) 9. SPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(5) 11. SPONSOR/MONITOR'S AGENCY NAME(5) AND ADDRESS(ES) 11. SPONSOR/MONITOR'S ACRONYM(5) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(5) 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive product cancer in two large US cohorts of medical accords from the Physicana", Health Study (PHS) and the Health Professionals Follow-up Study (HPFS). We have admost completed review of medical accords from the Physicana", Health Study (PHS) and the Health Professionals Follow-up Study (HPFS). We have admost completed review of medical accords from the Physicana", Health Study (PHS) and the Health Professionals Follow-up Study (HPFS). We have admost completed review of medical accords from the Physicana", Health Study (PHS) and the Health Professionals Follow-up Study (HPFS). We have admost completed review of medical accords from the Physicana", Health Study (PHS) and the Health Professionals Follow-up Study (HPFS). We have admost completed review of medical accords turror tissue ara					5c.	PROGRAM ELEMENT NUMBER		
G. AUTHOR(s) Lordel A. Mucci Jordel A. Mucci Jord								
Lorelei A. Murcci E-Mail: lorelei.mucci@hsph.harvard.edu 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Brigham and Women's Hospital Boston MA 02115 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer caese from the Physiciant Health Study (PPS) and the Health Professionals' Follow-up Study (PFS). We have almost completed review of medical records on whom are assembling as diminal datafile. Amaging the statistical analysis are underways are underways are underways and percent staining for these files markers has been evaluated by the approvaled to relate transfer signature associated with embed protestate cancer in statistical analysis are underways and percent staining for these files markers has been evaluated by the autoritic prostate cancer in the molecular signature associated with embed protestate cancer association of the molecular signature associated with embed protestate cancer in statistical analysis are underways and percent staining for these files markers has been evaluated by the autoritic prostate cancer in the older signature associated with embed protestate cancer in the molecular signature to predict poor prostate cancer association of the molecular signature to predict poor prostate cancer access in the PHS cases, and the Study (PFS). We have almost attendical analysis are underways and percent staining for these files markers has been evaluated by the autorities of markers. The statistical analysis are underways and percent statistical analysis are underways and percent statistical analysis are underways and percent statistical analysis are underw	6. AUTHOR(S)				5d.	PROJECT NUMBER		
E-Mail: lorelei.mucci@hsph.harvard.edu 5. TASK NUMBER F.PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 9. PERFORMING ORGANIZATION REPORT Brigham and Women's Hospital 0. PERFORMING ORGANIZATION REPORT Boston MA 02115 10. SPONSOR/MONITOR'S ACEONYM(S) IV.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACEONYM(S) Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S REPORT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S of prostate cancer aceases in the objective and the latel Professionals' Follow-up Study (HPFS). We have admost completed review of medical accords for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical admits. Among the 900 cases on whom the HSB coses, and statistical analyses are underway to absers the associated with thetal prostate cancer. 14. ABSTRACT: The current projects seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer aceases in the cohort, to abstract clinical data, and are assembling a clinical datalic. Among the 900 cases on whom throm than 6,000 prostate cancer cancer cancer. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USARNUC. 17. SUBJECT TERMS UU	Lorelei A. Mucci							
E-Mail: Iorelei.mucci@hsph.harvard.edu 5. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Brigham and Women's Hospital 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 12. SARTING TOR / MARING AGENCY NAME(S) AND ADDRESS(ES) 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT 13. SUPPLEMENTARY NOTES 14. ABSTRACT The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physiciant Health Study (PHS) and the Health Professional & Follow-up Study (HPES). We have almost completed review of medical records from the base microartins; we have undertaining to mean statistical angestion for the genes as part of a normal prostate cancer. Intensity and parcent staining for these five markers has been evaluated by the authoritation assess the association of the molecular signature to predict poor prostate cancer association of the molecular signature to predict poor prostate cancer association of the molecular signature to predict poor prostate cancer association of the molecular signature to predict poor prostate cancer association of the molecular signature to predict poor prostate cancer association of the molecular signature to predict poor prostate cancer a					5e.	TASK NUMBER		
E-Mail: lorelci.mucci@hsph.harvard.edu 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Brigham and Women's Hospital Boston MA 02115 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer ases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6.000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datalile. Armong the 900 cases on whom tumor tissue are outlaind on all statestical analyses are underway to assess the assembling a clinical datalile. Armong the 900 cases on whom tumor tissue are outlaind on all statestical analyses are underway to assess threas sees protein expression for five geness as ard of a recently identified molecular signature associated with leftal prostate cancer. Intensity and percent staining of these five markers has been evaluated by the pathologis for the PHS cases, and statestical analyses are underway to association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: U.U.9								
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Brigham and Women's Hospital 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S REPORT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project saeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cancer from the Physicans' Health Study (PHS) and the Health Professionals' Follow-up Study (PHFS). We have almost completed review of medical records from the Physicans' Health Study (PHS) and the Health Professionals' Follow-up Study (PHFS). We have almost completed review of medical records from the Physicans' Health Study (PHS) and the Health Professionals' Follow-up Study (PHFS). We have almost completed review of medical records from the Physicans' Health Study (PHS) and the Health Professionals' Follow-up Study (PHFS). We have almost completed review of medical records from the Physicans' Health Study (PHS) and the Health Professionals' Follow-up Study (PHFS). We have almost completed review of medical records from the Physicans' Health Study (PHS) and the Health Professionals' Follow-up Study (PHFS). We have almost completed review of medical records from the Physicans' Health Study (PHS) and the Health Professionals' Follow-up Study (PHS) and the health Professing Study (PHS) and the physicans' Health Study (PHS) and	E-Mail: lorelei.muco	ci@hsph.harvard.ed	lu		5f. V	WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Brigham and Women's Hospital 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 12. S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) 7. TO Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datalite. Arrong the 900 cases on whom turn tissue are contained on 8 databitica analyses are underway to assess the assembling a clinical datalite. Arrong the 900 cases on whom turn tissue are contained on 8 databitica analyses are underway to assess threas bene explaused on five genes as at of a recent y clanified molecular signature associated with lenal prostate cancer. Intensity and percent staining to These five markers has been evaluated by the pathologist for the PPS cases, and a statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survea. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 17. LIMITATION OF ASSTRACT 1		-						
Brigham and Women's Hospital Boston MA 02115 NUMBER 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited NUMBER(S) 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The ourrent project seaks to study molecular and clinical predictors of aggressive prostate cancer in two large US schools of prostate cancer reases from the Physicianis' Health Study (PHS) and the Health Professionals' Follow-up Study (HFF). We have a limited complex of meating a clinical alteriate cancer c	7. PERFORMING ORG	ANIZATION NAME(S) AND ADDRESS(ES)		8. F	PERFORMING ORGANIZATION REPORT		
Brigham and Women's Hospital Boston MA 02115 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 0.000 prostate cancer cancer cases from the ODM, to baster calinical administrate cancer. Intensity and percentisy and percenti	.				N	IUMBER		
Boston MA 02115 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 11. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The ourrent project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Handys, we have undersken immunohistochemistry to assess protein expression for five genes as part of a records for the more than 6.000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafie. Among the 900 cases on whom there outlands and statistical and adstatistical and adstatistical and statistical and attatistical and attatistical and statistical and statistical and statistical and statistical and antiges are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 18. NUMBER 19. NAME OF RESPONSIBLE PERSON 15. SUBJECT TERMS U U 19. TLINITATION 18. NUMBER 19	Brigham and Wom	en's Hospital						
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT NUMBER(S) Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records to the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datalle. Among the 900 cases on whom tumor lisue are contained on 8 lisue microarrays, we have undertaken immunohistochemistry to assess breim asterna to for the genes as part of a recently identified molecular signature association of the melical protein expression for five genes as part of a recently identified molecular signature association of the molecular signature to predict poor prostate cancer signature to predict poor prostate cancer search model building strategies for both sets of markers. 15. SUBJECT TERMS Instructure to predict poor prostate cancer in Markers. 16. SECURITY CLASSIFICATION OF: I1. LIMITATION OF ABSTRACT I18. NUMBER (include area or code) 0 A.BSTRACT C.THIS PAGE I19. LIMITATION INFORMENTINELEPHONE NUMBER (include area or code)	Boston MA 02115							
s. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) For Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the orbitate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Arong the 900 cases on whom tumor tissue are contained on 8 dissue microarrays, we have undertaken immunohistochemistry to assess protein expression for the genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and parcent staining of these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are undertaken immunohistochemistry to assess protein expression for the waluated by the resultable of the PHS cases, and statistical analyses are undertaken immunohistochemistry to assess protein expression for the selescase and o a recently identified molecular signature associated mole health Study (PHS). 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER (include area of a code) 18. SUBJECT TERMS No subject terms provided 19. ABSTRACT								
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow up Study (PHFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract chinical data data are assembling a clinical datafile. Amount of the genes as part of a recently identified molecular signature associated with leftal prostate cancer lenses for makers to subject assess the association of the genes as part of a recently identified molecular signature associated with leftal prostate cancer is subject therefore training for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 17. LIMITATION of ABSTRACT U 18. NUMBER of PAGES g 19a. NAME OF RESPONSIBLE PERSON USAMRMC								
9. SPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 10. S. Array Medicial Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (PHFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue accounting to a fissue microarray, we have undertaken immuchistochemistry to assess protein expression for the genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS case, and statistical analyses are undertaken immuchistochemistry to assess protein expression of the ordecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS 17. LIMITATION of EASTRACT 19a. NAME OF RESPONSIBLE PERSON 16. SECURITY CLASSIFICATION OF: 17. LIMITATION of PAGES 19a. NAME OF RESPONSIBLE PERSON 16. SECURITY CLASSIFICATION OF: U 19. ABSTRACT								
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (PHS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lehal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 16. SECURITY CLASSIFICATION OF: 17. LIMITATION of PAGES U 18. NUMBER of RESPONSIBLE PERSON 16. SECURITY CLASSIFICATION OF: 17. LIMITATION UU 9 19a. NAME OF RESPONSIBLE PERSON	9. SPONSORING / MO		NAME(S) AND ADDRES	S(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S)		
Fort Detrick, Maryland 217/02-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue accountarys, we have undertaken immunohistochemistry to assess protein expression for five genes so part of a recordly identified molecular signature associated with lenal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for be PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 16. SECURITY CLASSIFICATION OF: 17. LIMITATION of ABSTRACT 18. NUMBER of RESPONSIBLE PERSON USAMIRM. 19. MEPORT b. ABSTRACT c. THIS PAGE 17. LIMITATION of ABSTRACT 19. NAME OF RESPONSIBLE PERSON Code)	U.S. Army Medical	Research and Ma	ateriel Command					
11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data are assembling a clinical datafie. Among the 900 cases on whom turnor tissue are contained on 8 lissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION U 18. NUMBER of ABSTRACT 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE U 19 19a. NAME OF RESPONSIBLE PERSON	Fort Detrick, Maryla	and 21/02-5012						
NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 issue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 16. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 1 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES UU 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19a. NAME OF RESPONSIBLE PERSON USAMRMC a.REPORT U b. ABSTRACT U 11. NUMBER UU 18. NUMBER OF PAGES 19a. THEPONE NUMBER (include aree					11.	SPONSOR/MONITOR'S REPORT		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to astrate clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with thehal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature associated with thehal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS 17. LIMITATION of BASTRACT 18. NUMBER of RESPONSIBLE PERSON USAMINC a. REPORT U U 9 USAMIRMC						NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (PHFS). We have almost completed review of medical records for the more han 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for He PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 17. LIMITATION of ABSTRACT U 18. NUMBER OF PAGES U 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19. TELEPHONE NUMBER (include area code)								
Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assees the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION of ABSTRACT 18. NUMBER of RESPONSIBLE PERSON USAMRMC. 19. D. ABSTRACT c. THIS PAGE 0 9 UU 9	12. DISTRIBUTION / AVAILABILITY STATEMENT							
13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION of ABSTRACT 18. NUMBER of RESPONSIBLE PERSON USAMMED 19. ABSTRACT c. THIS PAGE U 9	Approved for Public Release; Distribution Unimited							
13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datalile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC 19. ABSTRACT 0. ABSTRACT 0. ABSTRACT 19a. NAME OF RESPONSIBLE PERSON USAMRMC								
13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases for the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC 19. NAME OF RESPONSIBLE PERSON UU 9								
13. SUPPLEMENTARY NOTES 14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6.000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE 9								
14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION of ABSTRACT 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE U 9	13. SUPPLEMENTARY NOTES							
14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC. 19. ABSTRACT C. THIS PAGE 19. LUL 9 9								
14. ABSTRACT: The current project seeks to study molecular and clinical predictors of aggressive prostate cancer in two large US cohorts of prostate cancer cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data, and are assembling a clinical datafile. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE U 9 U U U 9								
Cases from the Physicians Health Study (PFRS) and the Health Professionals Pollow-Up Study (HPRS). We have almost completed review of medical records for the more than 6,000 prostate cancer cases in the cohort, to abstract clinical data and are assembling a clinical data itiel. Among the 900 cases on whom tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: U 17. LIMITATION OF ABSTRACT 0 0. ABSTRACT 0 0. ABSTRACT 0 0. ABSTRACT 0 U 0 0 0 0 0 0 0 0 0 0 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON 0 0 19. TELEPHONE NUMBER (include area 0 0	14. ABSTRACT: The c	urrent project seeks to	o study molecular and clir	nical predictors of aggres	ssive prostate cand	cer in two large US cohorts of prostate cancer		
16. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 16. SECURITY CLASSIFICATION OF: 17. LIMITATION U 18. REPORT U 19. ABSTRACT U 19. ABSTRACT U	cases from the Physicians' Health Study (PHS) and the Health Professionals' Follow-up Study (HPFS). We have almost completed review of medical records							
recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 16. SECURITY CLASSIFICATION OF: 0. ABSTRACT 0. THIS PAGE U 10. THIS PAGE U 19. DU 19. TELEPHONE NUMBER (include area code)	tumor tissue are contained on 8 tissue microarrays, we have undertaken immunohistochemistry to assess protein expression for five genes as part of a							
pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers. 15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT U b. ABSTRACT U c. THIS PAGE U UU 9 19a. NAME OF RESPONSIBLE person USAMRMC	recently identified molecular signature associated with lethal prostate cancer. Intensity and percent staining for these five markers has been evaluated by the							
15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code)	pathologist for the PHS cases, and statistical analyses are underway to assess the association of the molecular signature to predict poor prostate cancer survival. The statistical team has discussed model building strategies for both sets of markers.							
15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT U 18. NUMBER OF PAGES U 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code)								
15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 0 D 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19. ABSTRACT U								
15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 0F ABSTRACT 0F PAGES U 10 10 11 12 13 14 15								
15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT U b. ABSTRACT U c. THIS PAGE U UU 9 19b. TELEPHONE NUMBER (include area code)								
15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code)								
15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT U b. ABSTRACT U c. THIS PAGE U UU 9 19b. TELEPHONE NUMBER (include area code)								
15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT U b. ABSTRACT U c. THIS PAGE U UU 9 19b. TELEPHONE NUMBER (include area code)								
15. SUBJECT TERMS No subject terms provided 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT C. THIS PAGE U U U 19a. NAME OF RESPONSIBLE PERSON U U U U U U U U U U								
Into subject terms provided 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT U b. ABSTRACT U c. THIS PAGE U UU 9 19b. TELEPHONE NUMBER (include area code)	13. SUBJECT TEKMS							
16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE UU 9 19b. TELEPHONE NUMBER (include area code)	ino subject terms p	IOVIDED						
16. SECURITY CLASSIFICATION OF:17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORT Ub. ABSTRACT Uc. THIS PAGE UUU919b. TELEPHONE NUMBER (include area code)								
a. REPORT Ub. ABSTRACT Uc. THIS PAGE UUUOF PAGES USAMRMCUSAMRMCa. REPORT Ub. ABSTRACT Uc. THIS PAGE U19b. TELEPHONE NUMBER (include area code)	16. SECURITY CLASS	IFICATION OF:		17. LIMITATION	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON		
a. REPORT b. ABSTRACT c. THIS PAGE 19b. TELEPHONE NUMBER (include area U U U U 9				UF ADSIKAUI	UF PAGES			
	a. REPORT	D. ABSTRACT	C. THIS PAGE			19b. TELEPHONE NUMBER (include area code)		
	U	U	U		9			
Standard Form 202 (Pour 9-00)				1		Standard Form 208 (Pey 8-08)		

Table of Contents

Introduction	4
Body	5
Key Research Accomplishments	6
Reportable Outcomes	7
Conclusions	8
References	.9
Appendices	

INTRODUCTION

Upon diagnosis with localized prostate cancer, patients and clinicians are faced with the decision of whether to treat or defer treatment. On one hand, prostate cancer is the second leading cause of cancer death among men in westernized countries (1), and deaths occur even 20 years after diagnosis (2). On the other, treatment has adverse effects (3) and is often unneeded, as most men die with and not from their cancer, and many harbor tumors that remain indolent even in the absence of therapy (2, 4)

Treatment of localized disease can reduce cancer mortality, but in the one randomized trial of radical prostatectomy versus watchful waiting (5, 6), the number needed to treat (NNT) to prevent one cancer death was 19. That trial predated screening by prostate specific antigen (PSA), where 30-60% of PSA-detected cancers may be characterized as overdiagnosed (7, 8) and the NNT may be greater.

There is a clear need for tools to correctly distinguish potentially lethal from indolent disease to guide clinical practice and treatment decisions. The Kattan nomogram characterizes risk of progression using pretreatment clinical markers: PSA levels, biopsy Gleason scores, and clinical stage (9, 10). This and other scoring systems (11, 12) have significant predictive power, but molecular tumor markers hold promise to improve prediction (13). However, few biomarkers studies have assessed their signatures to predict death from prostate cancer.

The current project seeks to examine molecular and clinical predictors of lethal prostate cancer within two large prostate cancer cohorts: the Physicians Health Study (PHS) and the Health Professionals Follow-up Study (HPFS). More than 6,000 men have developed incident prostate cancer in the cohorts, and these men have been followed prospectively for the development of metastases, cancer death, and death from other causes. Archival tumor tissue has been collected from 1,180 of the men, and is currently being constructed into tumor tissue microarrays for semi-quantitative Immunohistochemistry. Using this resource, the following aims will be explored:

- 1-) To test clinical nomograms to predict development of lethal prostate cancer in the PHS and HPFS cohorts.
- 2-) To test and validate molecular signatures in tumors to predict development of lethal disease, alone and independent of clinical markers.

BODY

Clinical record review.

We have completed abstraction of clinical parameters from medical records and pathology reports for 2,000 of the 2,240 incident PHS prostate cancers and 3,200 of the 3,800 incident HPFS prostate cancer cases. Data for these records have been scanned and undergone a process of verification to assess quality control of the data entry. Data abstraction should be finalized during the next three months. We have thoroughly reviewed the prostate cancer literature to identify the clinical nomograms that predict PSA relapse after prostatectomy. Once the clinical dataset is finalized, we will test these nomograms to predict lethal disease.

Follow-up data.

We have updated mortality data, including dates and causes of death, for the entire PHS and HPFS prostate cancer cohorts through 2006. These data have been reviewed by an Endpoints Committee and are available for analyses. Information on the development of distant metastases is derived from annual follow-up questionnaires on the cohorts. Participants, who are physicians and health professionals, self-report on site of metastases and date of diagnosis. We have undertaken a small validation study among men who did (N=65) and did not (N=35) report metastases, and have to date found high agreement between self-report and medical records. The follow-up data are finalized and outputted and stored on our UNIX server for analyses.

Tumor block collection.

We have now collected and catalogued archival tumor tissue from 1,100 men in the PHS (biopsy, TURP, prostatectomy tissue) and 780 men in the HPFS (prostatectomy only) prostate cancer cohorts. Our pathologist has undertaken centralized histopathologic review of all cases to confirm cancer, to provide standardized Gleason grading review, and to note other notable histologic features. We have now constructed high density tissue microarrays from the archival prostatectomy TURP and prostatectomy tissue for a total of 1,113 cases in the two cohorts. These TMAs will be used to increase efficiency of immunohistochemical evaluation.

Immunohistochemical evaluation and imaging.

Our group recently identified a five gene model that predicted death from prostate cancer in a Swedish Watchful Waiting Cohort. We seek to validate the signature in the HPFS and PHS prostate cancer cohorts. We have undertaken immunohistochemistry using antibodies against the five genes – cIAP, p63, MTA1, Jagged1, ABP280—on the PHS and HPFS TMAs. These images have been digitally scanned for imaging. The pathologist has reviewed the images for the first three PHS cases, digitally circling areas of tumor tissue. The intensity and percent staining for these three TMAs have been read by the Chromavision system, and we are about to begin preliminary data analysis to assess the predictive value of the molecular signature on development of lethal prostate cancer. The remaining six TMAs are now scheduled to be digitally reviewed by the pathologist in order for imaging to take place.

KEY RESEARCH ACCOMPLISHMENTS

- We have abstracted clinical data for 5,200 men with incident prostate cancer diagnosed in the PHS and HPFS cohorts.
- We have achieve long-term and complete clinical follow-up of the cohort with respect to development of metastases and cancer death, without loss to follow-up.
- We have assembled a large, population-based biorepository of archival tumor tissue, which has been catalogued and undergone histopathologic review.
- We have constructed nine high-density tissue microarrays (TMAs) from the tumor tissue.
- We have identified a five gene signature associated with lethal prostate cancer, and which we will validate in the PHS and HPFS cohorts. We have undertaken Immunohistochemistry to assess protein expression of the five genes across the nine TMAs.
- We will present preliminary data on the five gene model as a poster presentation at the upcoming Active Surveillance of Early Stage Prostate Cancer Meeting in San Francisco in January 2007.

REPORTABLE OUTCOMES

- Development of a prostate tumor biorepository for 1,800 men with incident prostate cancer, on whom there is long-term and complete clinical follow-up for development of distant metastases and cancer death.
- Preliminary results from the molecular signature will be presented as a poster presentation at a prostate cancer meeting:
 - Mucci LA, Stampfer M, Pawitan P, Demichelis F, Fall K, Adami HO, Andersson SO, Kantoff PW, Stark JR, Johannson JE, Rubin MA. Molecular signatures to predict lethal prostate cancer, Active Surveillance of Early Stage Prostate Cancer Meeting in San Francisco, January 2007
- Funding of this grant was instrumental in promoting the study PI to Assistant Professor in Medicine.

CONCLUSIONS

While the work for this project is ongoing, the preliminary data demonstrate our ability to undertake a large, population-based study of clinical and molecular predictors of aggressive prostate cancer. We have made significant progress on the data collection phase of the project, and have already successfully immunostained for five molecular markers of significant interest. This preliminary work with ensure that the project achieves the study aims by the end of the project period.

REFERENCES

1. Ferlay J BF, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality, and Prevalence Worldwide IARC CancerBase No. 5 version 2.0. In: IARC*Press*, Lyon; 2004.

2. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291(22):2713-9.

3. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347(11):790-6.

4. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. Jama 2005;293(17):2095-101.

5. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352(19):1977-84.

6. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-9.

7. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94(13):981-90.

 Ciatto S, Gervasi G, Bonardi R, et al. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 2005;41(3):411-5.
 Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90(10):766-71.

10. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98(10):715-7.

11. Partin AW, Piantadosi S, Sanda MG, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45(5):831-8.

12. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165(1):119-25.

13. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21(19):3573-9.